Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ANAB – AnaptysBio Inc

AnaptysBio, Inc.
ANAB
$24.69
Name : AnaptysBio, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $725,404,544.00
EPSttm : -4.76
finviz dynamic chart for ANAB
AnaptysBio, Inc.
$24.69
0.57%
$0.14

Float Short %

35.48

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

-0.29

EPS Last/This Y

-0.42

EPS This/Next Y

0.44

Price

24.69

Target Price

49

Analyst Recom

1.33

Performance Q

13.78

Relative Volume

0.56

Beta

-0.19

Ticker: ANAB




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04ANAB23.750.530.004020
2025-07-07ANAB23.460.542.504009
2025-07-08ANAB24.250.540.003999
2025-07-09ANAB25.740.540.233993
2025-07-10ANAB26.060.530.003998
2025-07-11ANAB26.220.530.674009
2025-07-14ANAB26.990.530.004013
2025-07-15ANAB26.60.530.004033
2025-07-16ANAB26.930.532.004036
2025-07-17ANAB26.690.520.004030
2025-07-18ANAB25.950.520.004029
2025-07-21ANAB26.110.133.331409
2025-07-22ANAB26.150.140.001426
2025-07-23ANAB26.990.140.001425
2025-07-24ANAB26.960.140.091426
2025-07-25ANAB26.950.140.141490
2025-07-28ANAB26.590.140.381491
2025-07-29ANAB26.170.143.301498
2025-07-30ANAB24.940.200.101581
2025-07-31ANAB24.520.190.881675
2025-08-01ANAB24.70.190.001675
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04ANAB23.759.6-31.5-5.42
2025-07-07ANAB23.499.6-30.3-5.42
2025-07-08ANAB24.259.6-39.7-5.42
2025-07-09ANAB25.749.6-45.3-5.42
2025-07-10ANAB26.099.6-35.4-5.42
2025-07-11ANAB26.209.6-36.2-5.42
2025-07-14ANAB26.959.6-38.1-5.42
2025-07-15ANAB26.639.6-30.4-5.42
2025-07-16ANAB26.879.6-34.4-5.42
2025-07-17ANAB26.689.6-31.5-5.42
2025-07-18ANAB25.939.6-27.3-5.42
2025-07-21ANAB26.139.6-34.2-5.42
2025-07-22ANAB26.179.6-33.0-5.42
2025-07-23ANAB27.009.6-38.6-5.42
2025-07-24ANAB26.999.6-32.7-5.42
2025-07-25ANAB26.949.6-32.2-5.42
2025-07-28ANAB26.649.6-30.6-5.54
2025-07-29ANAB26.227.5-30.1-5.54
2025-07-30ANAB24.987.5-23.3-5.54
2025-07-31ANAB24.557.5-29.1-5.54
2025-08-01ANAB24.697.5-33.9-5.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04ANAB-0.9122.9034.62
2025-07-07ANAB-0.9122.9034.62
2025-07-08ANAB-0.9122.9034.62
2025-07-09ANAB-0.9122.9034.62
2025-07-10ANAB-0.9122.9034.62
2025-07-11ANAB-0.9122.9035.41
2025-07-14ANAB-0.9123.0835.41
2025-07-15ANAB-0.9123.0835.41
2025-07-16ANAB-0.9123.0835.41
2025-07-17ANAB-0.9123.0835.41
2025-07-18ANAB-0.9123.0835.41
2025-07-21ANAB-0.9122.1335.41
2025-07-22ANAB-0.9122.1335.41
2025-07-23ANAB-0.9122.1335.41
2025-07-24ANAB-0.9122.1335.41
2025-07-25ANAB-0.9122.1335.48
2025-07-28ANAB-0.9122.2635.48
2025-07-29ANAB-0.9122.2635.48
2025-07-30ANAB-0.9122.2635.48
2025-07-31ANAB-0.9122.2635.48
2025-08-01ANAB-0.9122.2635.48
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.28

Avg. EPS Est. Current Quarter

-1.55

Avg. EPS Est. Next Quarter

-1.57

Insider Transactions

-0.91

Institutional Transactions

22.26

Beta

-0.19

Average Sales Estimate Current Quarter

11

Average Sales Estimate Next Quarter

11

Fair Value

Quality Score

22

Growth Score

53

Sentiment Score

5

Actual DrawDown %

40.2

Max Drawdown 5-Year %

-69.3

Target Price

49

P/E

Forward P/E

PEG

P/S

6.48

P/B

22.05

P/Free Cash Flow

EPS

-4.84

Average EPS Est. Cur. Y​

-5.54

EPS Next Y. (Est.)

-5.1

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-125.7

Relative Volume

0.56

Return on Equity vs Sector %

-437.1

Return on Equity vs Industry %

-418.4

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.11

EBIT Estimation

-33.9
AnaptysBio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 136
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
stock quote shares ANAB – AnaptysBio Inc Stock Price stock today
news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ANAB – AnaptysBio Inc yahoo finance google finance
stock history ANAB – AnaptysBio Inc invest stock market
stock prices ANAB premarket after hours
ticker ANAB fair value insiders trading